# IPX203 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ipx203

> The FDA approved IPX203, sponsored by Amneal Pharmaceuticals, Inc. (AMRX), on August 7, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is IPX203 FDA approved?

Yes. The FDA approved IPX203, sponsored by Amneal Pharmaceuticals, Inc. (AMRX), on August 7, 2024. SEC Form 10-K: "On August 7, 2024, the FDA approved our new drug application ("NDA") for CREXONT®, previously referred to as IPX203." [Calendar and source filings](https://sec-api.dev/pdufa/ipx203)

Source: SEC Form 10-K, accession 0001723128-25-000012, https://www.sec.gov/Archives/edgar/data/1723128/000172312825000012/amrx-20241231.htm (retrieved 2026-11-12). Last confirmed 2025-02-28. Cite: https://sec-api.dev/pdufa/ipx203#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | IPX203 |
| Codes | IPX203 |
| Sponsor | Amneal Pharmaceuticals, Inc. (AMRX) https://sec-api.dev/companies/amrx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### August 7, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2025-02-28.
- SEC Form 10-K (accession 0001723128-25-000012): "On August 7, 2024, the FDA approved our new drug application ("NDA") for CREXONT®, previously referred to as IPX203." https://www.sec.gov/Archives/edgar/data/1723128/000172312825000012/amrx-20241231.htm
- SEC Form 10-Q (accession 0001723128-24-000042): "On August 7, 2024, the FDA approved the Company's new drug application for CREXONT® (combination of carbidopa and levodopa extended release capsules), previously referred to as IPX203." https://www.sec.gov/Archives/edgar/data/1723128/000172312824000042/amrx-20240930.htm
- SEC Form 10-Q (accession 0001723128-24-000042): "On August 7, 2024, the FDA approved our new drug application for CREXONT®, previously referred to as IPX203." https://www.sec.gov/Archives/edgar/data/1723128/000172312824000042/amrx-20240930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ipx203.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IPX203 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ipx203

```bibtex
@misc{secapidev_pdufa_ipx203_20261116,
  title        = {IPX203 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ipx203}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ipx203_20261116","title":"IPX203 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ipx203","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
